ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) - USD ($)	3 Months Ended		9 Months Ended
5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Total stock-based compensation expense	$ 505,730	$ 262,963	$ 1,052,970	$ 996,088
Research and development
Total stock-based compensation expense	141,405	95,076	262,822	383,909
Plasma centers
Total stock-based compensation expense	10,341	15,289	36,288	40,044
Selling, general and administrative
Total stock-based compensation expense	331,946	152,598	726,062	572,135
Cost of goods sold
Total stock-based compensation expense	$ 22,038	$ 0	$ 27,798	$ 0